Loading stock…

Davide Campari-Milano N.V. (CPR) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

Davide Campari-Milano N.V.

CPRMarket cap $8.22BPrice $6.9

Country🇮🇹Italy

SectorConsumer

IndustryBeverages

Makes and distributes spirits like Aperol, Campari, and Wild Turkey across 190+ countries. Turned a bitter Italian aperitivo into a global cocktail-hour obsession, riding the Negroni renaissance to double-digit growth for over a decade.

In Bastion Portfolios?

52W Return+3%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+7%6

Revenue Forecast

Rev CAGR (1y)-4%2

Rev CAGR (3y)+3%3

Rev CAGR (5y)+4%4

Earnings Forecast

EPS Growth Y+1+7%6

EPS Growth Y+2+10%6

EPS Growth Y+3+9%6

Quality

Margins

EBIT Margin18%7

Net Income Margin9%5

Free Cash Flow Margin10%6

Debt

Net Debt/EBITDA3.23

Efficiency

ROE7%3

ROA3%5

Earnings Stability88

GEAR+WEAK29

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)na–

P/E Ratio (Forward 3y)164

P/BV1.87

EV Multiples

EV/EBITDA Fwd125

EV/EBIT Fwd156

Yield

Free Cash Flow Yield4.2%6

Dividend Yield1.6%4

Momentum

Short term

1 month return+6%9

3 month return+11%9

YTD return+12%7

Mid term

Price vs 52wHigh91%8

1 year return+10%6

Long term

3 year return-45%1

5 year return-49%1

Risk Shield

Price Risk

Beta0.85

Volatility34%6

Free Cash Flow

Free Cash Flow Margin10%6

Free Cash Flow Yield4.2%6

Quality

ROCE8%5

Earnings Stability88

Net Debt/EBITDA3.23

02Growth

Is it actually growing, and how fast?

CPRDavide Campari-Milano N.V.

Revenue FY25$3.6B

GROWTH RATING↗

WEAK28 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+7%6

Revenue, next 1Y-4%2

Revenue, next 3Y, CAGR+3%3

Revenue, next 5Y, CAGR+4%4

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+7%6

EPS growth, FY27E+10%6

EPS growth, FY28E+9%6

GROWTH ASSESSMENT

STRENGTHS

Earnings are set to grow faster than sales (EPS about 9%/yr vs revenue 3%/yr), so margins should widen.

WATCH

Revenue grew 7%/yr over the last 3 years; forecasts see it cooling to 3%/yr.

Over five years revenue is set to grow 4%/yr, behind 60% of companies worldwide.4/10

WEAKNESSES

Growth is the weak spot here, trailing 72% of companies worldwide.

Revenue is set to grow 3%/yr over the next 3 years, behind most of the market.3/10

BOTTOM LINE

Margin Expander

Growth is a weak point here: a business that is slowing. The one thing to watch: forward revenue growth trails the market.

03Price Momentum

Is the market behind it right now?

CPRDavide Campari-Milano N.V.

Total return Current49.5%

Price return Current40.2%

MOMENTUM RATING↗

AVERAGE57 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+6%9

3-month return+11%9

YTD return+12%7

MID & LONG-TERM▾SCORE

% of 52-week high91%8

1-year return+10%6

3-year return-45%1

5-year return-49%1

MOMENTUM ASSESSMENT

STRENGTHS

It's up 10% over the past year, but 9% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over the past month (+6%), over three months (+11%) and so far this year (+12%).

WATCH

None flagged.

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (-45% over three years and -49% over five), behind 90% of the market.

BOTTOM LINE

Early Turnaround

A poor multi-year track record but a sharp recent rally. Momentum is turning up, yet the trend is young and unproven — it needs follow-through to confirm rather than fade. The one thing to watch: the multi-year record is weak.

04Value

Are you paying a fair price for it?

Stop guessing on Davide Campari-Milano. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

CPRDavide Campari-Milano N.V.

Revenue FY25$3.6B

GROWTH RATING↗

WEAK28 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+7%6

Revenue, next 1Y-4%2

Revenue, next 3Y, CAGR+3%3

Revenue, next 5Y, CAGR+4%4

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+7%6

EPS growth, FY27E+10%6

EPS growth, FY28E+9%6

GROWTH ASSESSMENT

STRENGTHS

Earnings are set to grow faster than sales (EPS about 9%/yr vs revenue 3%/yr), so margins should widen.

WATCH

Revenue grew 7%/yr over the last 3 years; forecasts see it cooling to 3%/yr.

Over five years revenue is set to grow 4%/yr, behind 60% of companies worldwide.4/10

WEAKNESSES

Growth is the weak spot here, trailing 72% of companies worldwide.

Revenue is set to grow 3%/yr over the next 3 years, behind most of the market.3/10

BOTTOM LINE

Margin Expander

Growth is a weak point here: a business that is slowing. The one thing to watch: forward revenue growth trails the market.

03Price Momentum

Is the market behind it right now?

CPRDavide Campari-Milano N.V.

Total return Current49.5%

Price return Current40.2%

MOMENTUM RATING↗

AVERAGE57 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+6%9

3-month return+11%9

YTD return+12%7

MID & LONG-TERM▾SCORE

% of 52-week high91%8

1-year return+10%6

3-year return-45%1

5-year return-49%1

MOMENTUM ASSESSMENT

STRENGTHS

It's up 10% over the past year, but 9% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over the past month (+6%), over three months (+11%) and so far this year (+12%).

WATCH

None flagged.

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (-45% over three years and -49% over five), behind 90% of the market.

BOTTOM LINE

Early Turnaround

04Value

Are you paying a fair price for it?

Stop guessing on Davide Campari-Milano. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community